Vyne Therapeutics Inc expected to post a loss of 16  cents a share - Earnings Preview

YARROW BIOSCIENCE

02/05/2022 19:35

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 4
(estimated). 
    * The Bridgewater New Jersey-based  company is expected to
report 
a 91.1% decrease in revenue to $366.67 thousand from $4.12
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vyne Therapeutics
Inc is
for a loss of 16 cents per share. For the same quarter last
year, the company reported a loss of 37 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5​, above​ its last closing price of $0.42. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.20       -0.24      -0.20     Beat    15.5
 Sep. 30 2021  -0.32       -0.32      -0.36     Missed  -11.6
 Jun. 30 2021  -0.35       -0.35      -0.35     Met     1.1​
 Mar. 31 2021  -0.39       -0.41      -0.37     Beat    9.3
 ​​Dec.        -0.53       -0.54      -0.55     Missed  -2.6
 31 2020                                                
 Sep. 30 2020  -0.68       -0.67      -0.60     Beat    10.3​
 Jun. 30 2020  -0.93       -0.99      -0.80     Beat    19.5
 Mar. 31 2020  -2.04       -2.16      -3.80     Missed  -75.9
 This summary was machine generated May 2 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated